Abstract:Human immunodeficiency virus type-1 and hepatitis C virus (HIV/HCV) coinfection occurs when a patient is simultaneously infected with both human immunodeficiency virus type-1 (HIV-1) and hepatitis C virus (HCV), which is common today in certain populations. However, the treatment of coinfection is a challenge because of the special considerations needed to ensure hepatic safety and avoid drug–drug interactions. Multitarget inhibitors with less toxicity may provide a promising therapeutic strategy for HIV/HCV coinfection. However, the identification of one molecule that acts on multiple targets simultaneously by experimental evaluation is costly and time-consuming. In silico target prediction tools provide more opportunities for the development of multitarget inhibitors. In this study, by combining Naïve Bayes (NB) and support vector machine (SVM) algorithms with two types of molecular fingerprints, MACCS and extended connectivity fingerprints 6 (ECFP6), 60 classification models were constructed to predict compounds that were active against 11 HIV-1 targets and four HCV targets based on a multiple quantitative structure–activity relationships (multiple QSAR) method. Five-fold cross-validation and test set validation were performed to measure the performance of the 60 classification models. Our results show that the 60 multiple QSAR models appeared to have high classification accuracy in terms of the area under the ROC curve (AUC) values, which ranged from 0.83 to 1 with a mean value of 0.97 for the HIV-1 models and from 0.84 to 1 with a mean value of 0.96 for the HCV models. Furthermore, the 60 models were used to comprehensively predict the potential targets of an additional 46 compounds, including 27 approved HIV-1 drugs, 10 approved HCV drugs and nine selected compounds known to be active against one or more targets of HIV-1 or HCV. Finally, 20 hits, including seven approved HIV-1 drugs, four approved HCV drugs, and nine other compounds, were predicted to be HIV/HCV coinfection multitarget inhibitors. The reported bioactivity data confirmed that seven out of nine compounds actually interacted with HIV-1 and HCV targets simultaneously with diverse binding affinities. The remaining predicted hits and chemical-protein interaction pairs with the potential ability to suppress HIV/HCV coinfection are worthy of further experimental investigation. This investigation shows that the multiple QSAR method is useful in predicting chemical-protein interactions for the discovery of multitarget inhibitors and provides a unique strategy for the treatment of HIV/HCV coinfection.

Novel Strategy for Screening Target Proteins by the Common Drugs─Sofosbuvir-Specific Profiling of HCV Patient Serum

Selective Profiling of Liver-Related Specific Proteins Based on Sofosbuvir-Modified Magnetic Separation Material

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Virus-like Iron-Gold Heterogeneous Nanoparticles for Drug Target Screening

Application Of Chemistry-Based Functional Proteomics To Screening For Novel Drug Targets

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

High throughput proteome screening for novel drug targets

A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity

An unbiased immunoaffinity-based strategy for profiling covalent drug targets in vivo.

Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy

Targeting HIV/HCV Coinfection Using a Machine Learning-Based Multiple Quantitative Structure-Activity Relationships (multiple QSAR) Method.

Solvent-induced protein precipitation for drug target discovery on proteomic scale.

Utilizing solid-state nanopore sensing for high-efficiency and precise targeted localization in antiviral drug development

Primary Research on the Different Expressions of Serum Proteomics in HCV-infected Patients

Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions.

Recent Advances in Screening Methods Enabling the Discovery of Novel Anti-Hepatitis B Virus Drug Candidates

A Universal Strategy Designed for Selecting Bench-to-bedside Aptamers to Serum and Validated in Hepatocellular Carcinoma Diagnosis

Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index Than Sorafenib via Zebrafish Drug Screening Platform

Target-centric analysis of hepatitis B: identifying key molecules and pathways for treatment

An economical, high-throughput protein-protein interaction modulator drug screening technique based on surface-enhanced Raman scattering

Targeting against HIV/HCV Co-infection using Machine Learning-based multitarget-quantitative structure-activity relationships (mt-QSAR) Methods